Ethylmalonic Acid

Your body is constantly breaking down fats for energy inside tiny cell compartments called mitochondria (the energy factories in your cells). When one specific step in that process stumbles, a small acid called ethylmalonic acid starts spilling into your urine. Measuring it gives you a chemical snapshot of whether short-chain fat breakdown is running smoothly.

This test is most commonly used in children and infants suspected of having an inborn error of metabolism. Its established clinical role is in evaluating suspected fatty-acid oxidation disorders and related rare conditions. Higher levels have also shown up in early pregnancy before gestational diabetes appears, in people with chronic pain, and during acute illnesses where energy metabolism is under stress, but these adult applications are preliminary findings from small studies and have not been validated for routine clinical use.

What This Marker Actually Reflects

Ethylmalonic acid (EMA) is not a hormone, protein, or enzyme. It is a small organic acid (a metabolite) formed when a specific enzyme called short-chain acyl-CoA dehydrogenase (SCAD) does not fully do its job. SCAD normally helps break down short-chain fats inside mitochondria. When SCAD activity is reduced, the unprocessed building block (butyryl-CoA) gets diverted into making ethylmalonic acid, which then shows up in urine.

SCAD dysfunction is not the only path to elevated EMA. In ethylmalonic encephalopathy, changes in the ETHE1 gene cause hydrogen sulfide to build up, which secondarily blocks SCAD activity and drives EMA higher through a different mechanism than a primary SCAD defect.

This is a specialty research-grade marker (an internal classification used on this platform, not a standard medical designation). It does not have universal cutpoints for adults, and a single reading should not be used to make a diagnosis in isolation. Its strongest established role is in evaluating suspected fatty-acid oxidation disorders and certain rare conditions, while emerging research is starting to connect it to metabolic risk patterns in adults.

Short-Chain Acyl-CoA Dehydrogenase Deficiency

Persistent elevation of ethylmalonic acid is one of the clearest biochemical signals of short-chain acyl-CoA dehydrogenase deficiency (SCADD), a condition where the SCAD enzyme does not work properly. The clinical picture ranges from completely normal to symptoms such as low blood sugar, low muscle tone, developmental delay, seizures, and metabolic acidosis (a buildup of acid in the blood).

A common gene variant called 625G greater than A (also called G209S) is strongly over-represented in people who excrete a lot of EMA. In one study of 135 patients with elevated EMA, about 60 percent were homozygous for this variant and 30 percent were heterozygous. The variant is also common in the general population, with roughly 7 percent homozygous and 35 percent heterozygous. Under current nomenclature (GeneReviews), the common variants such as c.625G>A and c.511C>T are now classified as benign rather than disease-causing, so a high EMA result driven by these variants reflects a biochemical pattern, not a diagnosis on its own.

Ethylmalonic Encephalopathy

Markedly elevated urinary EMA is also a hallmark of ethylmalonic encephalopathy, a rare genetic disorder caused by changes in the ETHE1 gene. Affected infants typically show severe developmental delay, chronic diarrhea, blue-purple skin discoloration (acrocyanosis), and pinpoint skin hemorrhages, along with high lactate and methylsuccinic acid in body fluids.

This condition is rare and almost always diagnosed in early childhood. If you are an adult ordering this test for your own metabolic insight, ethylmalonic encephalopathy is not what you are screening for, but understanding it helps explain why the test exists in metabolic panels in the first place.

Gestational Diabetes Risk

One practical adult finding comes from a small study in early pregnancy that compared 25 women who later developed gestational diabetes with 25 controls. Women who later developed gestational diabetes had higher median urinary ethylmalonate at around 17 weeks of pregnancy. Women in the highest third of EMA had odds of developing gestational diabetes about 11 times higher than those in the lowest third (odds ratio 11.4), but the 95 percent confidence interval was very wide (1.10 to 117.48), meaning the true effect could be much smaller or much larger than that point estimate.

What this means for you: if you are early in pregnancy or planning one, an elevated urinary EMA can be an early hint that your fatty-acid metabolism is under strain, well before your blood sugar starts to drift. Because the study was small and the confidence interval was so wide, this is best treated as one signal among several, not as a stand-alone test for gestational diabetes risk.

Chronic Pain and Symptom Burden

In active-duty service members with chronic pain, urinary ethylmalonic acid appeared in a urine pain indicator along with kynurenic acid and other metabolites. Individually, higher EMA was associated with worse self-reported fatigue, anxiety, depression, and physical functioning. A follow-up post-treatment analysis found the broader urine metabolite pattern, including EMA, remained linked to pain outcomes. The original study used a liberal significance threshold (p of 0.10 or less), so these associations should be considered exploratory.

This does not mean EMA causes pain. It suggests that some people with chronic pain have shifts in cellular energy metabolism that show up in urine, and EMA is one trackable piece of that pattern.

Acute Illness and Metabolic Stress

Urinary EMA can spike during severe acute illness. In a study of people with severe malaria, urinary EMA rose along with several other organic acids and contributed to the metabolic acidosis seen in critical cases. In a child with a known multiple acyl-CoA dehydrogenase defect, EMA shifted from a small fraction of total urinary organic acids when she was well to a much larger fraction during acute episodes.

The takeaway: a single high reading during illness, recovery, or major physical stress may reflect a temporary metabolic crunch rather than a chronic problem. Timing your test outside of acute illness matters.

Nonspecific Brain Function and Other Associations

Research has found that mild, silent EMA elevations in urine were more common in people with unexplained brain dysfunction than in healthy controls. Separately, serum (not urine) ethylmalonic acid has appeared in diagnostic models that help distinguish prostatitis from benign prostatic enlargement and prostate cancer subgroups, though these are early findings using a different specimen than the urine test discussed here.

Tracking Your Trend

A single ethylmalonic acid reading is a snapshot. Levels can vary day to day depending on what you ate, whether you were fasting, your physical activity, and whether you have been ill. In one case study, EMA shifted substantially as a share of total urinary organic acids depending on metabolic state. That kind of variability is exactly why a trend matters more than a single number.

A practical approach if your clinician has recommended monitoring: get a baseline reading when you are healthy and well-fed, retest in 3 to 6 months if you are making meaningful changes to diet, exercise, or supplements, and consider an annual recheck after that. Because this is a research-grade marker without validated adult cutpoints, results should be interpreted in context with other tests and clinical history rather than against a single threshold.

When Results Can Be Misleading

Several factors can push a single reading in a direction that does not reflect your steady-state metabolism. Lead with these when interpreting results:

• Acute illness or metabolic crisis: EMA can rise sharply during severe infection, fasting stress, or recovery from a major illness, and may return to baseline once you recover.
• Kidney function and age: Related organic acids (such as methylmalonic acid) rise with declining kidney filtration and with age. A meaningful share of variation in similar markers is explained by kidney function, vitamin B12, age, and sex.
• Recent diet and fasting: Loading on medium-chain fats or going through a prolonged fast can shift urinary organic acid patterns within days.
• Underlying genetic variants: Common SCAD gene variants (now classified as benign under current nomenclature) are present in a substantial portion of the general population and can produce mild EMA elevations without disease.

Collecting the Specimen Correctly

Urinary ethylmalonic acid is typically measured against creatinine to adjust for how concentrated or dilute your sample is. A first-morning urine often gives the most stable reading because you have not been eating, drinking, or exercising for hours. Avoid heavy exercise the day before, do not change your diet sharply in the 24 to 48 hours before collection, and try to test when you are well rather than recovering from illness.

What an Unexpected Result Should Make You Do

If your urinary EMA comes back high, the right next steps depend on the pattern, not on hitting a specific number. Repeat the test on a fresh sample after a few weeks, ideally when you are not ill, not fasting, and have not made recent dietary changes. A reading that stays elevated across two or three samples deserves more attention than one off result.

Pair an elevated EMA with related tests that fill out the picture: a plasma acylcarnitine profile (especially C4, butyrylcarnitine) to evaluate fatty-acid oxidation, methylmalonic acid and homocysteine to check vitamin B12 status, and a basic kidney panel to rule out filtration changes. If multiple markers in this pathway are abnormal, or if you have a family history of metabolic disease, talk with a metabolic specialist or genetic counselor. EMA alone rarely settles a diagnosis, but it can be the thread that opens a useful workup.